Matches in SemOpenAlex for { <https://semopenalex.org/work/W2243320223> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2243320223 abstract "e13000 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that forms peri-vascular tracks and promotes endothelial cell adhesion and survival. These activities are inhibited by the huMAb anti-EGFL7 (MEGF0444A), which significantly enhances the efficacy of anti-VEGF in murine tumor models. A Phase Ia dose escalation of single agent MEGF0444A demonstrated no dose-limiting toxicities (DLTs). Methods: A standard 3+3 dose escalation design was used to study safety, PK, PD, and anti-tumor activity of MEGF0444A in a 2-arm Phase Ib trial in patients (pts) with advanced solid tumors. In Arm A, 22 pts received MEGF0444A at doses of 2, 5, or 10 mg/kg with bev 10 mg/kg q2w. In Arm B, 18 pts additionally received paclitaxel 90 mg/m 2 weekly. Subsequent Arm A expansion cohorts have examined flat dosing of MEGF0444A (600 mg) as a rapid infusion, serial tumor biopsies, and pts with renal cell carcinoma (RCC), respectively. Circulating progenitor cells (CPCs) and dynamic contrast enhanced MRI (DCE-MRI) were assessed as PD biomarkers. Results: The combination of MEGF0444A and bev with or without paclitaxel was well-tolerated without DLTs, exacerbation of bev-related adverse events (AEs), or AEs attributed to rapid infusion. MEGF0444A demonstrated linear PK, and flat dosing yielded MEGF0444A exposures similar to those predicted using Phase Ia weight-based dosing data. CPCs decreased in a subset of pts at the 5 mg/kg q2w dose. DCE-MRI showed a trend toward decreased K trans at this dose, supporting combination activity with bev. Eight partial responses, 2 in Arm A and 6 in Arm B, were observed across multiple tumor types. Conclusions: MEGF0444A has demonstrated safety, favorable PK, and clinical activity in combination with bev and bev/paclitaxel. PD biomarker modulation supports a recommended Phase II dose equivalent to 5 mg/kg q2w. RCC and tumor biopsy cohorts remain active. Randomized Phase II trials of MEGF0444A in combination with chemotherapy and bev in colorectal cancer and non-small cell lung cancer are underway." @default.
- W2243320223 created "2016-06-24" @default.
- W2243320223 creator A5022154227 @default.
- W2243320223 creator A5033313503 @default.
- W2243320223 creator A5033960518 @default.
- W2243320223 creator A5036134937 @default.
- W2243320223 creator A5037497042 @default.
- W2243320223 creator A5038215538 @default.
- W2243320223 creator A5044122805 @default.
- W2243320223 creator A5047573588 @default.
- W2243320223 creator A5049416849 @default.
- W2243320223 creator A5068949418 @default.
- W2243320223 creator A5069690249 @default.
- W2243320223 creator A5083373965 @default.
- W2243320223 creator A5084564240 @default.
- W2243320223 creator A5087092015 @default.
- W2243320223 date "2012-05-20" @default.
- W2243320223 modified "2023-09-22" @default.
- W2243320223 title "Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel." @default.
- W2243320223 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e13000" @default.
- W2243320223 hasPublicationYear "2012" @default.
- W2243320223 type Work @default.
- W2243320223 sameAs 2243320223 @default.
- W2243320223 citedByCount "0" @default.
- W2243320223 crossrefType "journal-article" @default.
- W2243320223 hasAuthorship W2243320223A5022154227 @default.
- W2243320223 hasAuthorship W2243320223A5033313503 @default.
- W2243320223 hasAuthorship W2243320223A5033960518 @default.
- W2243320223 hasAuthorship W2243320223A5036134937 @default.
- W2243320223 hasAuthorship W2243320223A5037497042 @default.
- W2243320223 hasAuthorship W2243320223A5038215538 @default.
- W2243320223 hasAuthorship W2243320223A5044122805 @default.
- W2243320223 hasAuthorship W2243320223A5047573588 @default.
- W2243320223 hasAuthorship W2243320223A5049416849 @default.
- W2243320223 hasAuthorship W2243320223A5068949418 @default.
- W2243320223 hasAuthorship W2243320223A5069690249 @default.
- W2243320223 hasAuthorship W2243320223A5083373965 @default.
- W2243320223 hasAuthorship W2243320223A5084564240 @default.
- W2243320223 hasAuthorship W2243320223A5087092015 @default.
- W2243320223 hasConcept C111113717 @default.
- W2243320223 hasConcept C112705442 @default.
- W2243320223 hasConcept C126322002 @default.
- W2243320223 hasConcept C159654299 @default.
- W2243320223 hasConcept C203014093 @default.
- W2243320223 hasConcept C2776694085 @default.
- W2243320223 hasConcept C2777292972 @default.
- W2243320223 hasConcept C2777472916 @default.
- W2243320223 hasConcept C2777802072 @default.
- W2243320223 hasConcept C542903549 @default.
- W2243320223 hasConcept C71924100 @default.
- W2243320223 hasConcept C98274493 @default.
- W2243320223 hasConceptScore W2243320223C111113717 @default.
- W2243320223 hasConceptScore W2243320223C112705442 @default.
- W2243320223 hasConceptScore W2243320223C126322002 @default.
- W2243320223 hasConceptScore W2243320223C159654299 @default.
- W2243320223 hasConceptScore W2243320223C203014093 @default.
- W2243320223 hasConceptScore W2243320223C2776694085 @default.
- W2243320223 hasConceptScore W2243320223C2777292972 @default.
- W2243320223 hasConceptScore W2243320223C2777472916 @default.
- W2243320223 hasConceptScore W2243320223C2777802072 @default.
- W2243320223 hasConceptScore W2243320223C542903549 @default.
- W2243320223 hasConceptScore W2243320223C71924100 @default.
- W2243320223 hasConceptScore W2243320223C98274493 @default.
- W2243320223 hasLocation W22433202231 @default.
- W2243320223 hasOpenAccess W2243320223 @default.
- W2243320223 hasPrimaryLocation W22433202231 @default.
- W2243320223 hasRelatedWork W1606837855 @default.
- W2243320223 hasRelatedWork W1821030679 @default.
- W2243320223 hasRelatedWork W2101433461 @default.
- W2243320223 hasRelatedWork W2123967535 @default.
- W2243320223 hasRelatedWork W2161317196 @default.
- W2243320223 hasRelatedWork W2240276766 @default.
- W2243320223 hasRelatedWork W2245320394 @default.
- W2243320223 hasRelatedWork W2255135986 @default.
- W2243320223 hasRelatedWork W2261189152 @default.
- W2243320223 hasRelatedWork W2274050005 @default.
- W2243320223 hasRelatedWork W2274465999 @default.
- W2243320223 hasRelatedWork W2277441235 @default.
- W2243320223 hasRelatedWork W2588494329 @default.
- W2243320223 hasRelatedWork W2595795832 @default.
- W2243320223 hasRelatedWork W2604130272 @default.
- W2243320223 hasRelatedWork W2611689931 @default.
- W2243320223 hasRelatedWork W2739968211 @default.
- W2243320223 hasRelatedWork W2740815887 @default.
- W2243320223 hasRelatedWork W2752875184 @default.
- W2243320223 hasRelatedWork W2775602799 @default.
- W2243320223 isParatext "false" @default.
- W2243320223 isRetracted "false" @default.
- W2243320223 magId "2243320223" @default.
- W2243320223 workType "article" @default.